Overview SPP100 (Aliskiren) Regimen in Patients With Severe Hypertension Status: Completed Trial end date: 2006-11-01 Target enrollment: Participant gender: Summary Assessing the safety and efficacy of SPP100 (Aliskiren) regimen in patients with severe hypertension Phase: Phase 3 Details Lead Sponsor: Novartis